213 Validation of the EAU Biochemical Recurrence Risk Groups for Predicting Outcomes After Salvage Focal Therapy for Radiorecurrent Prostate Cancer
British Journal of Surgery · 10.07.2026 · 113 (Supplement_6)
DOI: 10.1093/bjs/znag063.736 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 10.07.2026. Verfasst von R D Patel und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Aim
For localised radiorecurrent prostate cancer, salvage focal ablative therapy might be an effective and less-morbid alternative to whole-gland options. EAU risk groups for patients with biochemical recurrence (BCR) after radiotherapy have not been evaluated in the focal salvage setting. We aimed to validate the EAU BCR risk groups in a prospective cohort of salvage focal therapy patients.
Method
Men treated with focal high-intensity focal ultrasound (HIFU) or focal cryotherapy for radiorecurrent prostate cancer between 2017-2024 were identified from the HEAT and ICE prospective registries. Patients were stratified as high-risk if they had pre-radiotherapy grade group 4-5 disease or time to biochemical failure ≤18 months; others were classified as low-risk. Kaplan-Meier analysis and multivariable Cox regression assessed associations with biochemical failure (Phoenix definition) and treatment failure (metastasis, local retreatment excluding one redo salvage procedure, initiation of androgen deprivation therapy, or cancer-specific death), adjusting for age, pre-salvage grade group, and salvage modality.
Results
Eighty-five patients were included (HIFU n=52; cryotherapy n=33), of whom 19 (21%) were high-risk. Median follow-up was 24.6 months. 5-year BCR-free survival was 0.58 for high-risk and 0.71 (for low-risk patients. High-risk status was not independently associated with biochemical failure (HR 1.99, 95% CI 0.68–5.81; p=0.2). 5-year treatment failure-free survival was 0.32 and 0.48 for high- and low-risk patients, respectively.
Conclusions
EAU BCR risk groups, originally validated for progression and survival after post-radiotherapy recurrence, did not discriminate for treatment failure after focal salvage therapy. Longer follow-up with larger numbers of patients are required.
Zitieren
APA
Patel, R. D., Gopalakrishnan, A., Mayor, N., Bertoncelli-Tanaka, M., Arya, M., Ahmed, H. U., Shah, T. T., & Light, A. (2026). 213 Validation of the EAU Biochemical Recurrence Risk Groups for Predicting Outcomes After Salvage Focal Therapy for Radiorecurrent Prostate Cancer. British Journal of Surgery, 113(Supplement_6). https://doi.org/10.1093/bjs/znag063.736
Vancouver
Patel RD, Gopalakrishnan A, Mayor N, Bertoncelli-Tanaka M, Arya M, Ahmed HU, et al. 213 Validation of the EAU Biochemical Recurrence Risk Groups for Predicting Outcomes After Salvage Focal Therapy for Radiorecurrent Prostate Cancer. British Journal of Surgery. 2026;113(Supplement_6). doi:10.1093/bjs/znag063.736
BibTeX
@article{Patel2026,
author = {Patel, R D and Gopalakrishnan, A and Mayor, N and Bertoncelli-Tanaka, M and Arya, M and Ahmed, H U and Shah, T T and Light, A},
title = {213 Validation of the EAU Biochemical Recurrence Risk Groups for Predicting Outcomes After Salvage Focal Therapy for Radiorecurrent Prostate Cancer},
journal = {British Journal of Surgery},
year = {2026},
volume = {113},
number = {Supplement_6},
doi = {10.1093/bjs/znag063.736}
}
EUVIMED